A meta-analysis including 5 randomized clinical trials reported an increased risk of systemic hypertension (RR: 1.49; 95% CI: 1.12-1.98]) that occurred in 19.5% of patients treated with combination of BRAF inhibitor and MEK inhibitor compared with 14% in the BRAF inhibitor monotherapy group.9 The gene discussed is MAP2K7; the disease is Hypertension.